Robert Schreiber, PhD

Andrew M. and Jane M. Bursky Distinguished Professor, Pathology & Immunology

Additional Titles

  • Interim Chief, Division of Immunobiology
  • Director, Center for Human Immunology and Immunotherapy Programs
  • Co-Leader, Tumor Immunology Program Siteman comprehensive
  • Cancer Center Director, T32 Training Grant in the Immunobiology and Cell Biology of Cancer (NCI)

Additional Professional Memberships

  • Extramural Member Researcher, Parker Institute for Cancer Immunotherapy
  • Member, Board of Scientific Advisors, National Cancer Institute
  • Associate Director, Scientific Advisory Board
  • Cancer Research institute Co-Editor in Chief, Cancer Immunology Research


  • BA: (Chemistry) State University of NY at Buffalo (1968)
  • PhD: (Biochemistry/Immunology) State University of New York at Buffalo (1973)
  • Postdoc: (Immunology) Research institute of Scripps Clinic (1973-1976)


  • Fellow of the AACR Academy (2019)
  • Honoris Causa Diploma, University of Buenos Aires (2017)
  • Balzan Prize (Shared with James Allison): Immunological Approaches in Cancer Therapy (2017)
  • Organizer, Keystone Symposium, “Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (2017)
  • Member, Biden Blue Ribbon Panel on Cancer Moonshot (2016)
  • Organizer, Society for Immunotherapy of Cancer, “Workshop on New Perspectives (2015)
  • Heath Memorial Award, The University of Texas MD Anderson Cancer Center (2015)
  • AACR Lloyd J. Old Prize in Cancer Immunology (2014)
  • Organizer, Inaugural Meeting of International Cytokine and Interferon Society (2013)
  • Member, National Academy of Sciences (2012)
  • Member, American Academy of Arts and Science (2010)
  • Carl and Gerty Cori Faculty Achievement Award, Washington University (2008)
  • Distinguished Investigator Award, Washington University School of Medicine (2008)
  • The Charles Rodolphe Brupbacher Prize for Cancer Research (2007)
  • Member, Kennedy Institute of Rheumatology, Scientific Advisory Board (2002)
  • Organizer, Keystone Symposium, “Jaks and Stats: Development to Disease” (2004)
  • Associate Director of the Scientific Advisory Council, Cancer Research Institute (2002-)
  • Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute (1996)
  • Marie T. Bonazinga Award for Excellence in Leukocyte Biology Research (1998)
  • Fellow of the American Association for the Advancement of Science (1996)
  • Milstein Award for Outstanding Achievements in Interferons and Cytokines International Society of Interferon and Cytokine Research (1996)
  • Merit Award Grant #CA 43059, National Cancer Institute (1995-2002)
  • Recipient, American Heart Association Established Investigatorship 77-202 (1977-1982)
  • Recipient, National Institutes of Health Predoctoral Fellowship (1970-1972)

Clinical Interests

  • Immunotherapy of Cancer
  • Development of Patient-Specific Cancer Neoantigen Vaccines
  • Immunomonitoring of Cancer Immunotherapy
  • High Dimensional Analysis (scRNASeq, CyTOF, CODEX) of Successful Versus Unsuccessful Cancer Immunotherapy

Research Interests

My research is focused on elucidating the cellular and molecular mechanisms underlying natural and therapeutically induced immune responses to developing and established cancers. My group was the first to propose the concept of “Cancer Immunoediting” wherein the immune system not only protects against cancer but also favors cancer outgrowth by shaping tumor cell immunogenicity. We went on to provide strong experimental evidence supporting each of the three phases of the cancer immunoediting process—Elimination, Equilibrium and Escape. We produced a variety of gene-targeted mice and used them to obtain genetic evidence for the roles of various cytokines, receptors and signaling pathways in the cancer immunoediting process. In the process, we also developed a model of mouse mammary cancer that displays remarkable similarities to human luminal breast cancer. During my career, my lab generated a number of key monoclonal antibody reagents that neutralize cytokines or block cytokine receptors and validated their in vivo use to assess the role of cytokines in preventing or inducing diseases particularly cancer.

Most recently, my group pioneered the use of immunogenomics approaches to rapidly identify immunogenic tumor-specific neoantigens and target them therapeutically. Our work now focuses on optimizing the use of therapeutic neoantigen vaccines (in combination with other forms of cancer therapy and immunotherapy) to treat solid and hematopoietic malignancies. In all, my 44 years of laboratory based research has led to the publication of in 267 peer-reviewed papers and 64 reviews resulting yielding an h-index of 124 (ISI Web of Science).

In addition to my primary research career, I have also been consistently involved in graduate and postdoctoral trainee education. I have mentored 27 Ph.D. students (including 13 MD/PhD students) and 39 postdocs, led the Immunology Training Program at Washington University from 1993-2003 and was the Director of the T32 Program in Immunology for 10 years. In 2003 I stepped down from those positions to take over as Director of the NCI T32 funded program in Cancer Biology (now the T32 Program in the Immunobiology and Cell Biology of Cancer) since it more closely aligned to my research interests. I have led that program for 18 years.

DBBS Affiliation List

  • Immunology Program


Pub Med Search

Meraz MA, White MJ, Sheehan KFC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431-442 (1996) PMID:8608597
Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KCF, Yin L, Pennica D, Johnson EM, Schreiber, RD. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373-383 (1998) PMID:9590172
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci (U S A) 95(13):7556-7561 (1998) PMCID:PMC22681
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111 (2001) PMID:11323675
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907 (2007) PMID:18026089
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565-1570 (2011) PMID:21436444
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400-404 (2012) PMCID:PMC3874809
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens. Nature 515:577-581 (2014) PMCID:PMC4279952a
Gubin MM*, Esaulova E*, Ward JP*, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RF, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KC, Oh ST, Schreiber RD#, Artyomov MN#. High Dimensional Analysis Delineates Myeloid and Lympoid Compartment Remodeling During Successful Immune Checkpoint Cancer Therapy. Cell 175(4):1014-1030 (2018). * First three authors contributed equally. #Senior authors contributed equally. PMCID:PMC6541402
Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng Wm Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574:696-701(2019) PMCID:PMC6858572

Jeanne Grigsby

Lab Phone: 314-362-8746
Office Location: BJC-IH Building, Office Suite C  8417